[Anxiety and depression during chemotherapy for lymphoproliferative diseases].
In order to analyse anxiety and depression states observed during the treatment of lymphoproliferative diseases, a group of 23 patients were studied. For assessment of the variables the following was used: history taking, psychological observation and psychometric techniques. The obtained results point to various dynamics of anxiety and depression. The intensity of anxiety states decreases during single as well as successive courses of chemotherapy. Depression states intensify during one course with a tendency for mood lowering with prolonged treatment duration. Therapeutic conclusions: 1. It is necessary to minimize anxiety attitudes, particularly during the first phase of the treatment (cognitive psychotherapy). 2. In deep depression it is indicated to use antidepressants and supportive psychotherapy.
Piusińska
A
A
V Kliniki Chorób Wewnetrznych, Warszawie.
Sułek
K
K
Ilnicki
S
S
Betiuk
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001007:Anxiety / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003863:Depression / Q000139:chemically induced* / Q000628:therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone